# A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma

Source: https://onco.cc/trials/nct07124936/  
OnCo record `nct07124936` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Gemcitabine, CAPOX, Cyclophosphamide in diffuse large b-cell lymphoma, run by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma is a phase 1/2 interventional study registered as NCT07124936 by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., with 97 participants planned, started 2025-07-30 and due to reach its primary completion in 2027-10-26. Interventions recorded: HDM2005, Rituximab or Rituximab biosimilar, Gemcitabine, Oxaliplatin, Cyclophosphamide. Conditions listed: Diffuse Large B Cell Lymphoma (DLBCL). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07124936
- Phase: 1/2
- Setting: A Phase 1b/2 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
- Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- Enrolled: 97

## Sources

- ClinicalTrials.gov NCT07124936: https://clinicaltrials.gov/study/NCT07124936

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- drugs: [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Prednisone](https://onco.cc/drugs/prednisone/)

---
JSON: https://onco.cc/api/v1/entities/nct07124936.json